The pharmacogenomics of sex hormone metabolism: Breast cancer risk in menopausal hormone therapy

Pharmacogenomics

Volumn 13, Issue 6, 2012, Pages 659-675

  Justenhoven, Christina ^a   Obazee, Ofure ^a   Brauch, Hiltrud ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

breast cancer risk; estrogen metabolism; hormone therapy; menopause; pharmacogenomics; polymorphisms

Indexed keywords

CELL NUCLEUS RECEPTOR; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; FOLIC ACID; GESTAGEN; GROWTH FACTOR; PLACEBO; PROGESTERONE; SEX HORMONE; STEROID; TAMOXIFEN;

ABCB1 GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL CYCLE REGULATION; CYP17A1 GENE; DNA DAMAGE; DRUG EFFICACY; FGFR2 GENE; FOLATE METABOLISM; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HORMONE ACTION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; MDR1 GENE; MENOPAUSE; MONOTHERAPY; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PHARMACOGENOMICS; POSTMENOPAUSE; RAD51 GENE; REVIEW; RISK ASSESSMENT; TREATMENT DURATION;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADAL STEROID HORMONES; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS, HORMONE-DEPENDENT; POLYMORPHISM, GENETIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84859945426     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.144     Document Type: Review

References (137)

1. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5(3), 207-213 (2004). (Pubitemid 38402112)
2. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360(9337), 942-944 (2002). (Pubitemid 35283842)
3. Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362(9382), 419-427 (2003). (Pubitemid 36999703)
4. Chlebowski RT, Anderson GL, Gass M et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15), 1684-1692 (2010).
5. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288(3), 321-333 (2002). (Pubitemid 34761611)
6. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006). (Pubitemid 43261982)
7. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004). (Pubitemid 38715141)
8. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. Circulation 123(15), 1661-1670 (2011).
9. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011).
10. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow-up of a randomised controlled trial. Lancet Oncol. 12(3), 236-244 (2011).
11. Brauch H, Jordan VC. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur. J. Cancer 45(13), 2274-2283 (2009).
12. Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55(10), 1770-1782 (2009).
13. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
14. Murdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase 1 and 2 enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89(5), 708-717 (2011).
15. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
16. Schroth W, Hamann U, Fasching PA et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res. 16(17), 4468-4477 (2010).
17. Stearns V, Rae JM. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev. Mol. Med. 10, e34 (2008).
18. Beatson GT. On the threatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 148(3802), 104 (1896).
19. Clemons M, Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 344(4), 276-285 (2001). (Pubitemid 32108534)
20. Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat. Res. 462(2-3), 323-333 (2000). (Pubitemid 30190238)
21. Santen RJ, Leszczynski D, Tilson-Mallet N et al. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann. NY Acad. Sci. 464, 126-137 (1986). (Pubitemid 17197627)
22. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 11(3), 206 (2009).
23. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J. Clin. Oncol. 24(12), 1823-1830 (2006). (Pubitemid 46638979)
24. Key T, Appleby P, Barnes I, Reeves G; Endogenous hormones and breast cancer collaborative group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst. 94(8), 606-616 (2002). (Pubitemid 34498648)
25. Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 76(8), 812-815 (2011).
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
27. Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15(4), 278-290 (2008).
28. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354(3), 270-282 (2006).
29. Russo J, Hasan Lareef M, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid Biochem. Mol. Biol. 87(1), 1-25 (2003). (Pubitemid 37421335)
30. Hayes CL, Spink DC, Spink BC et al. 17 b-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl Acad. Sci. USA 93(18), 9776-9781 (1996). (Pubitemid 26296685)
31. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J. Natl Cancer Inst. Monogr. (27), 75-93 (2000).
32. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. 21(1), 40-54 (2000). (Pubitemid 32260395)
33. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 61(18), 6716-6722 (2001). (Pubitemid 32896493)
34. Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by conjugation. J. Natl Cancer Inst. Monogr. 27, 113-124 (2000).
35. Yao J, Chang M, Li Y et al. Inhibition of cellular enzymes by equine catechol estrogens in human breast cancer cells: specificity for glutathione S-transferase P1-1. Chem. Res. Toxicol. 15(7), 935-942 (2002). (Pubitemid 34774448)
36. Yao J, Li Y, Chang M et al. Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase. Chem. Res. Toxicol. 16(5), 668-675 (2003). (Pubitemid 36613101)
37. Li Y, Yao J, Chang M et al. Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant form of catechol-O-methyltransferase. Chem. Res. Toxicol. 17(4), 512-520 (2004). (Pubitemid 38506985)
38. Haynes BP, Straume AH, Geisler J et al. Intratumoral estrogen disposition in breast cancer. Clin. Cancer Res. 16(6), 1790-1801 (2010).
39. Lonning PE, Helle H, Duong NK et al. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J. Steroid Biochem. Mol. Biol. 117(1-3), 31-41 (2009).
40. Gunnarsson C, Hellqvist E, Stal O. 17b-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br. J. Cancer 92(3), 547-552 (2005). (Pubitemid 40395536)
41. Miyoshi Y, Ando A, Hasegawa S et al. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin. Cancer Res. 9(6), 2288-2293 (2003). (Pubitemid 36687654)
42. Suzuki T, Nakata T, Miki Y et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 63(11), 2762-2770 (2003). (Pubitemid 36667146)
43. Ellis MJ, Miller WR, Tao Y et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res. Treat. 116(2), 371-378 (2009).
44. Kallstrom AC, Salme R, Ryden L et al. 17ss-hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. Eur. J. Cancer 46(5), 892-900 (2010).
45. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 29(2), 217-233 (2008). (Pubitemid 351519691)
46. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276(40), 36869-36872 (2001).
47. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
48. Anstead GM, Carlson KE, Katzenellenbogen JA. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62(3), 268-303 (1997). (Pubitemid 27114399)
49. Schutze N, Vollmer G, Knuppen R. Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells. J. Steroid Biochem. Mol. Biol. 48(5-6), 453-461 (1994). (Pubitemid 24171870)
50. Pawlak KJ, Wiebe JP. Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites. J. Steroid Biochem. Mol. Biol. 107(3-5), 172-179 (2007). (Pubitemid 47380373)
51. Shyamala G, Chou YC, Louie SG et al. Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. J. Steroid Biochem. Mol. Biol. 80(2), 137-148 (2002). (Pubitemid 34233736)
52. Wiebe JP. Progesterone metabolites in breast cancer. Endocr. Relat. Cancer 13(3), 717-738 (2006). (Pubitemid 44763254)
53. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J. Gen. Intern. Med. 23(9), 1507-1513 (2008).
54. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer: Lancet 350(9084), 1047-1059 (1997).
55. Flesch-Janys D, Slanger T, Mutschelknauss E et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int. J. Cancer 123(4), 933-941 (2008). (Pubitemid 352032424)
56. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J. Clin. Oncol. 27(31), 5138-5143 (2009).
57. LaCroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305(13), 1305-1314 (2011).
58. Li CI, Malone KE, Porter PL et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24), 3254-3263 (2003). (Pubitemid 37430078)
59. Magnusson C, Baron JA, Correia N et al. Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int. J. Cancer 81(3), 339-344 (1999). (Pubitemid 29165190)
60. Saxena T, Lee E, Henderson KD et al. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol. Biomarkers Prev. 19(9), 2366-2378 (2010).
61. Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283(4), 485-491 (2000). (Pubitemid 30062864)
62. Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J. The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control 21(1), 83-90 (2010).
63. Desantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol. Biomarkers Prev. 20(5), 733-739 (2011).
64. Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. Trends in hormone therapy and breast cancer incidence-results from the German network of cancer registries. Pathobiology 76(2), 90-97 (2009).
65. Chlebowski RT, Kuller LH, Prentice RL et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360(6), 573-587 (2009).
66. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 291(14), 1701-1712 (2004). (Pubitemid 38489892)
67. Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a 'new' biology of estrogen-induced apoptosis. Cancer Prev. Res. (Phila.). 4(5), 633-637 (2011).
68. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br. J. Cancer 92(11), 2049-2058 (2005). (Pubitemid 40897429)
69. Antoniou AC, Wang X, Fredericksen ZS et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat. Genet. 42(10), 885-892 (2010).
70. Dunning AM, Healey CS, Baynes C et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum. Mol. Genet. 18(6), 1131-1139 (2009).
71. Gold B, Kirchhoff T, Stefanov S et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl Acad. Sci. USA 105(11), 4340-4345 (2008). (Pubitemid 351754382)
72. Masciari S, Larsson N, Senz J et al. Germline E-cadherin mutations in familial lobular breast cancer. J. Med. Genet. 44(11), 726-731 (2007). (Pubitemid 350155461)
73. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42(5), 410-414 (2010).
74. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin. Cancer Res. 14(24), 7988-7999 (2008).
75. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39(7), 865-869 (2007). (Pubitemid 47014497)
76. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40(6), 703-706 (2008). (Pubitemid 351748861)
77. Thomas G, Jacobs KB, Kraft P et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41(5), 579-584 (2009).
78. Turnbull C, Ahmed S, Morrison J et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 42(6), 504-507 (2010).
79. Zheng W, Long J, Gao YT et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet. 41(3), 324-328 (2009).
80. Hardy J, Singleton A. Genomewide association studies and human disease. N. Engl. J. Med. 360(17), 1759-1768 (2009).
81. Prentice RL, Huang Y, Hinds DA et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol. Biomarkers Prev. 18(11), 3079-3085 (2009).
82. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB et al. CYP17 and breast cancer risk: the polymorphism in the 5́ flanking area of the gene does not influence binding to Sp-1. Cancer Res. 59(12), 2825-2828 (1999). (Pubitemid 29283117)
83. Feigelson HS, Shames LS, Pike MC et al. Cytochrome P450c17a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58(4), 585-587 (1998). (Pubitemid 28099459)
84. Haiman CA, Hankinson SE, Spiegelman D et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 59(5), 1015-1020 (1999). (Pubitemid 29135960)
85. Chen Y, Gammon MD, Teitelbaum SL et al. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29(4), 766-771 (2008). (Pubitemid 351494164)
86. The MARIE-GENICA consortium on genetic susceptibility for menopausal hormone therapy related breast cancer risk. Genetic polymorphisms in phase 1 and phase 2 enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res. Treat. 119(2), 463-474 (2010).
87. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1-34-T>C polymorphism. Breast Cancer Res. Treat. 120(3), 737-744 (2010).
88. Justenhoven C, Pierl CB, Haas S et al. The CYP1B1-1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res. Treat. 111(1), 171-177 (2008). (Pubitemid 352009231)
89. Pesch B, Ko Y, Brauch H et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur. J. Epidemiol. 20(8), 699-711 (2005). (Pubitemid 41266867)
90. Cribb AE, Knight MJ, Dryer D et al. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol. Biomarkers Prev. 15(3), 551-558 (2006).
91. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392(6), 1093-1108 (2008).
92. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur. J. Clin. Pharmacol. 62(10), 877-880 (2006). (Pubitemid 44521437)
93. Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103-113 (2006). (Pubitemid 43069582)
94. Justenhoven C, Hamann U, Pierl CB et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res. Treat. 115(2), 391-396 (2009).
95. Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309-317 (2009).
96. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553-2560 (2009).
97. Ashton KA, Proietto A, Otton G et al. Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 116(8), 1053-1061 (2009).
98. Lurie G, Wilkens LR, Thompson PJ et al. Genetic polymorphisms in the estrogen receptor b (ESR2) gene and the risk of epithelial ovarian carcinoma. Cancer Causes Control 20(1), 47-55 (2009).
99. The MARIE-GENICA consortium on genetic susceptibility for menopausal hormone therapy related breast cancer risk. Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int. J. Cancer 126(12), 2935-2946 (2010).
100. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22(15), 3181-3186 (1994). (Pubitemid 24260654)
101. Irvine RA, Ma H, Yu MC et al. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum. Mol. Genet. 9(2), 267-274 (2000). (Pubitemid 30052750)
102. Westberg L, Baghaei F, Rosmond R et al. Polymorphisms of the androgen receptor gene and the estrogen receptor b gene are associated with androgen levels in women. J. Clin. Endocrinol. Metab. 86(6), 2562-2568 (2001). (Pubitemid 32545707)
103. Xie W, Evans RM. Orphan nuclear receptors: the exotics of xenobiotics. J. Biol. Chem. 276(41), 37739-37742 (2001).
104. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148), 1087-1093 (2007). (Pubitemid 47014426)
105. Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39(7), 870-874 (2007). (Pubitemid 47014500)
106. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23(20), 3501-3508 (2004). (Pubitemid 38658416)
107. Moffa AB, Ethier SP. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J. Cell Physiol. 210(3), 720-731 (2007). (Pubitemid 46188288)
108. Carroll JS, Meyer CA, Song J et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38(11), 1289-1297 (2006). (Pubitemid 44646291)
109. Allouche A, Nolens G, Tancredi A et al. The combined immunodetection of AP-2a and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res. 10(1), R9 (2008).
110. Baritaki S, Suzuki E, Umezawa K et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J. Immunol. 180(9), 6199-6210 (2008).
111. Lee BC, Lee TH, Zagozdzon R et al. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1a)-mediated breast cancer cell migration. Cancer Res. 65(7), 2840-2845 (2005). (Pubitemid 40490087)
112. Rebbeck TR, DeMichele A, Tran TV et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis 30(2), 269-274 (2009).
113. Rebbeck TR, Troxel AB, Norman S et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int. J. Cancer 120(7), 1523-1528 (2007). (Pubitemid 46355388)
114. Slattery ML, Sweeney C, Wolff R et al. Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in southwestern United States. Breast Cancer Res. Treat. 104(2), 197-209 (2007). (Pubitemid 47084224)
115. Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol. 48(1), 1-9 (2011).
116. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res. Treat. 120(3), 727-736 (2010).
117. Barnes DM, Camplejohn RS. P53, apoptosis, and breast cancer. J. Mammary Gland Biol. Neoplasia 1(2), 163-175 (1996).
118. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26(2), 180-185 (2004). (Pubitemid 38501215)
119. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm. Res. 21(7), 1284-1293 (2004). (Pubitemid 38954215)
120. Ichikawa-Haraguchi M, Sumizawa T, Yoshimura A et al. Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland. Biochim. Biophys. Acta 1158(3), 201-208 (1993). (Pubitemid 23348994)
121. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43), 5864-5874 (2006). (Pubitemid 44453442)
122. Welsch PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10(7), 705-713 (2001).
123. Scully R, Chen J, Plug A et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88(2), 265-275 (1997). (Pubitemid 28015875)
124. Yeh S, Hu YC, Rahman M et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl Acad. Sci. USA 97(21), 11256-11261 (2000).
125. Schnyder S, Du NT, Le HB et al. Estrogen treatment induces MLL aberrations in human lymphoblastoid cells. Leuk. Res. 33(10), 1400-1404 (2009).
126. Tsutsui T, Tamura Y, Yagi E, Barrett JC. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17b-estradiol and eight of its metabolites. Int. J. Cancer 86(1), 8-14 (2000). (Pubitemid 30133980)
127. Fan S, Wang J, Yuan R et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284(5418), 1354-1356 (1999). (Pubitemid 29289660)
128. Quick SK, Shields PG, Nie J et al. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 17(5), 1082-1087 (2008).
129. McCann SE, Ip C, Ip MM et al. Dietary intake of conjugated linoleic acids and risk of premenopausal and postmenopausal breast cancer, Western New York Exposures and Breast cancer study (WEB Study). Cancer Epidemiol. Biomarkers Prev. 13(9), 1480-1484 (2004). (Pubitemid 39202315)
130. Ahn J, Nowell S, McCann SE et al. Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol. Biomarkers Prev. 15(6), 1217-1222 (2006).
131. Bastaki M, Huen K, Manzanillo P et al. Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. Pharmacogenet. Genom. 16(4), 279-286 (2006).
132. Nadif R, Mintz M, Jedlicka A et al. Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli. Free Radic. Res. 39(12), 1345-1350 (2005). (Pubitemid 43023799)
133. Chen Y, Shen L, Zhang F et al. The equine estrogen metabolite 4-hydroxyequilenin causes DNA single-strand breaks and oxidation of DNA bases in vitro. Chem. Res. Toxicol. 11(9), 1105-1111 (1998). (Pubitemid 28447301)
134. Zhang F, Chen Y, Pisha E et al. The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an O-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-O-quinone. Chem. Res. Toxicol. 12(2), 204-213 (1999). (Pubitemid 29096070)
135. Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE. MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev. 13(12), 2071-2077 (2004). (Pubitemid 40054300)
136. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64(3), 169-172 (1998). (Pubitemid 28453294)
137. Chung CC, Chanock SJ. Current status of genome-wide association studies in cancer. Hum. Genet. 130(1), 59-78 (2011).